Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mylan beta-blocker approvable
Final approval of nebivolol is contingent upon successfully satisfying additional FDA requirements regarding certain aspects of the preclinical data and finalization of the labeling. The preclinical data submitted
Final approval of nebivolol is contingent upon successfully satisfying additional FDA requirements regarding certain aspects of the preclinical data and finalization of the labeling. The preclinical data submitted
The primary objective of the double-blind, placebo-controlled trial, known as ACTIVE, is to determine the safety of Ventavis (iloprost) inhalation solution in patients with pulmonary hypertension (PH) associated
In anticipation of the submission to the Medicines and Healthcare products Regulatory Agency (MHRA) of a protocol for the commencement of phase III clinical trials evaluating diabetes treatment
The agreements are structured in two phases. During the research collaboration phase, Hybridon and Novartis will work together to evaluate novel immune modulatory (IMO) compounds from which Novartis
The new model aims to stem the widespread problem of counterfeit drug distribution by enabling item-level authentication by a pharmacy in a non-internet-connected environment. This means the drug
The acquisition builds on a successful two-year collaboration between Affymetrix and ParAllele that has enabled scientists to access more genomic information, in less time and for less money,
Meloxicam is usually used for the treatment of pain, inflammation or swelling caused by osteoarthritis and may also be used in conditions such as rheumatoid arthritis or ankylosing
The current participant numbers represent approximately 65% of the 342 patients required to be enrolled in the trial. As originally projected, the company expects to complete enrollment on
Adventrx has also received the necessary regulatory and ethical approvals to begin trialing the drug, its lead drug candidate, in the UK, Germany, Romania, Serbia and India. Applications
Alpharma expects the collaboration to significantly accelerate the expansion of its global generic product pipeline in line with company strategy. Ten products with global brand sales exceeding $20